AR090572A1 - Derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos - Google Patents
Derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticosInfo
- Publication number
- AR090572A1 AR090572A1 ARP130101067A ARP130101067A AR090572A1 AR 090572 A1 AR090572 A1 AR 090572A1 AR P130101067 A ARP130101067 A AR P130101067A AR P130101067 A ARP130101067 A AR P130101067A AR 090572 A1 AR090572 A1 AR 090572A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl
- heterocycloalkyl
- independently
- hydrogen atom
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 11
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 9
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000001424 substituent group Chemical group 0.000 abstract 5
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000005843 halogen group Chemical group 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 2
- 125000004181 carboxyalkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 abstract 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 abstract 1
- XXJGBENTLXFVFI-UHFFFAOYSA-N 1-amino-methylene Chemical compound N[CH2] XXJGBENTLXFVFI-UHFFFAOYSA-N 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 229910003827 NRaRb Inorganic materials 0.000 abstract 1
- -1 amino , hydroxyl Chemical group 0.000 abstract 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 150000003573 thiols Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Professional, Industrial, Or Sporting Protective Garments (AREA)
Abstract
Proceso para su preparación y su uso terapéutico. Reivindicación 1: Un compuesto de fórmula (1) donde: R⁶ es -CONH₂ o un grupo -C(Rᵃ)(Rᵇ)(OH) en el que Rᵃ y Rᵇ son, independientemente entre sí, un átomo de hidrógeno o un grupo alquilo C₁₋₆ o forman juntos, con el átomo de carbono que los porta, un carbociclo de 3 a 5 miembros; R es un grupo fenilo o heteroarilo sustituido con R¹, R¹, R² y R³; R¹ es un átomo de hidrógeno o se selecciona entre siguientes grupos: alquilo C₁₋₆, alcoxi C₁₋₆, cicloalquilo C₃₋₇ y arilo, estando estos grupos opcionalmente sustituidos con uno o varios sustituyentes, independientemente en cada caso, seleccionados entre: amino, hidroxilo, tiol, halógeno, alquilo C₁₋₆, alcoxi C₁₋₆, alquiltio C₁₋₆, alquilamino C₁₋₆, ariloxi, arilalcoxi C₁₋₆, ciano, haloalquilo C₁₋₆, carboxilo y carboxialquilo C₁₋₆; R¹ es un átomo de hidrógeno o un grupo alcoxi C₁₋₆; R² se selecciona entre: un átomo de hidrógeno, un átomo de halógeno, o un grupo alquilo C₁₋₆, cicloalquilo C₃₋₇ o alcoxi C₁₋₆; un grupo heterocicloalquilo, heterocicloalquil-CH₂- o heteroarilo; donde cada uno de dichos grupos heterocicloalquilo, heterocicloalquil-CH₂- y heteroarilo está opcionalmente sustituido con uno o varios sustituyentes, independientemente en cada caso, seleccionados entre: alquilo C₁₋₆, cicloalquilo C₃₋₇, alcoxi C₁₋₆, heterocicloalquilo, carboxialquilo C₁₋₆, NR⁴R⁵ y OR⁴; estando dicho grupo alquilo C₁₋₆ opcionalmente sustituido con un átomo de halógeno o un grupo alcoxi C₁₋₆, heterocicloalquilo, NH₂ u OH; y siendo cada uno de R⁴ y R⁵, independientemente el uno del otro, un átomo de hidrógeno, un grupo alquilo C₁₋₆ o un grupo heterocicloalquilo o también R⁴ y R⁵ forman juntos, con el átomo de nitrógeno que los porta, un anillo de 4 a 7 miembros; un grupo NRᵃRᵇ, donde Rᵃ y Rᵇ son, independientemente entre sí: un átomo de hidrógeno; un grupo heterocicloalquilo, estando dicho grupo heterocicloalquilo opcionalmente sustituido con un grupo alquilo C₁₋₆; o un grupo alquilo C₁₋₆, estando dicho grupo alquilo opcionalmente sustituido con un grupo NR⁴R⁵; siendo cada uno de R⁴ y R⁵, independientemente el uno del otro, un átomo de hidrógeno, un grupo alquilo C₁₋₆ o un grupo heterocicloalquilo; o también R⁴ y R⁵ forman juntos, con el átomo de nitrógeno que los porta, un anillo de 4 a 7 miembros; R³ es un átomo de hidrógeno, un átomo de halógeno o un grupo alquilo C₁₋₆; donde, cuando R es un grupo fenilo, dos sustituyentes adyacentes en el grupo fenilo pueden formar juntos un anillo heterocicloalquilo condensado con el fenilo que los porta, estando este heterocicloalquilo opcionalmente sustituido con uno o varios sustituyentes, independientemente en cada caso, seleccionados entre: un grupo oxo y un grupo alquilo C₁₋₆; R⁷ es un grupo arilo o grupo heteroarilo estando este grupo opcionalmente sustituido con uno o varios sustituyentes, independientemente en cada caso, seleccionados entre: ciano, halógeno, alquilo C₁₋₆, OR⁴, CH₂OH, CH₂NH₂, S(O)ₙR⁴, R⁸ y OR⁸; donde: R⁴ es un átomo de hidrógeno o un grupo alquilo C₁₋₆ o arilo, estando dichos grupos alquilo y arilo opcionalmente sustituidos con un átomo de halógeno o un grupo NH₂ u OH; n es 1 ó 2; y R⁸ es un grupo haloalquilo C₁₋₆; donde cada uno del átomo o átomos de nitrógeno de los compuestos de fórmula (1) puede estar, independientemente el uno del otro, opcionalmente en forma oxidada (N-óxido); o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1253044A FR2988722B1 (fr) | 2012-04-03 | 2012-04-03 | Nouveaux derives de thienopyrimidines, leurs procedes de preparation et leurs utilisations therapeutiques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR090572A1 true AR090572A1 (es) | 2014-11-19 |
Family
ID=48095815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130101067A AR090572A1 (es) | 2012-04-03 | 2013-04-03 | Derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos |
Country Status (37)
| Country | Link |
|---|---|
| US (6) | US9115140B2 (es) |
| EP (1) | EP2834248B1 (es) |
| JP (1) | JP6096278B2 (es) |
| KR (1) | KR102039764B1 (es) |
| CN (2) | CN107652303B (es) |
| AR (1) | AR090572A1 (es) |
| AU (1) | AU2013244992B2 (es) |
| BR (1) | BR112014024489B1 (es) |
| CA (1) | CA2868685C (es) |
| CL (1) | CL2014002661A1 (es) |
| CO (1) | CO7091179A2 (es) |
| CR (1) | CR20140435A (es) |
| CY (1) | CY1117843T1 (es) |
| DK (1) | DK2834248T3 (es) |
| DO (1) | DOP2014000216A (es) |
| EA (1) | EA025558B1 (es) |
| ES (1) | ES2577382T3 (es) |
| FR (1) | FR2988722B1 (es) |
| HR (1) | HRP20160649T1 (es) |
| HU (1) | HUE027895T2 (es) |
| IL (1) | IL234960A (es) |
| MA (1) | MA37384B1 (es) |
| MX (1) | MX355104B (es) |
| MY (1) | MY166151A (es) |
| PE (1) | PE20150289A1 (es) |
| PH (1) | PH12014502180A1 (es) |
| PL (1) | PL2834248T3 (es) |
| PT (1) | PT2834248E (es) |
| RS (1) | RS54850B1 (es) |
| SG (1) | SG11201406091RA (es) |
| SI (1) | SI2834248T1 (es) |
| TN (1) | TN2014000415A1 (es) |
| TW (1) | TWI579288B (es) |
| UA (1) | UA112685C2 (es) |
| UY (1) | UY34725A (es) |
| WO (1) | WO2013150036A1 (es) |
| ZA (1) | ZA201407021B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2988722B1 (fr) * | 2012-04-03 | 2014-05-09 | Sanofi Sa | Nouveaux derives de thienopyrimidines, leurs procedes de preparation et leurs utilisations therapeutiques |
| AU2015266492B2 (en) * | 2014-05-28 | 2017-11-02 | Fochon Pharmaceuticals, Ltd. | Certain protein kinase inhibitors |
| AU2016251253B2 (en) * | 2015-04-24 | 2020-07-09 | Guangzhou Maxinovel Pharmaceuticals Co., Ltd | Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof |
| CN113549069A (zh) * | 2015-12-27 | 2021-10-26 | 重庆复创医药研究有限公司 | 一类激酶抑制剂 |
| JP6927548B2 (ja) | 2016-05-07 | 2021-09-01 | シャンハイ フォチョン ファーマシューティカル カンパニー リミテッド | ある種のタンパク質キナーゼ阻害剤 |
| BR112020005174A2 (pt) | 2017-09-14 | 2020-11-10 | Daiichi Sankyo Company,Limited | composto que possui estrutura cíclica |
| SMT202200134T1 (it) | 2018-03-08 | 2022-05-12 | Incyte Corp | Composti di amminopirazindiolo come inibitori di pi3k-y |
| CN110551142B (zh) | 2018-05-31 | 2023-05-12 | 上海再极医药科技有限公司 | 一种稠环嘧啶类化合物的盐、晶型及其制备方法和应用 |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
| CA3121202A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| CN110922421B (zh) * | 2019-12-17 | 2023-05-05 | 安徽英特美科技有限公司 | 一种n-甲基-1,2,5,6-四氢吡啶-4-硼酸频哪醇酯的合成方法 |
| CN113384582A (zh) * | 2020-03-13 | 2021-09-14 | 广州再极医药科技有限公司 | 稠环嘧啶化合物在制备治疗癌症的药物中的应用 |
| WO2023169461A1 (zh) * | 2022-03-08 | 2023-09-14 | 广州再极医药科技有限公司 | 一种噻吩并嘧啶类化合物、中间体、其制备方法、组合物和应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1470356A1 (de) * | 1964-01-15 | 1970-04-30 | Thomae Gmbh Dr K | Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung |
| CN1280580A (zh) | 1997-11-11 | 2001-01-17 | 辉瑞产品公司 | 用作抗癌药的噻吩并嘧啶和噻吩并吡啶衍生物 |
| WO2000075145A1 (en) | 1999-06-03 | 2000-12-14 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| DE10042997A1 (de) | 2000-09-01 | 2002-03-14 | Merck Patent Gmbh | Thienopyrimidine |
| WO2007084815A2 (en) | 2006-01-19 | 2007-07-26 | Janssen Pharmaceutica, N.V. | Substituted thienopyrimidine kinase inhibitors |
| TW200801012A (en) * | 2006-04-26 | 2008-01-01 | Piramed Ltd | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
| PL2091918T3 (pl) | 2006-12-08 | 2015-02-27 | Novartis Ag | Związki i kompozycje jako inhibitory kinazy białkowej |
| ES2564422T3 (es) | 2007-11-15 | 2016-03-22 | Ym Biosciences Australia Pty Ltd | Compuestos heterocíclicos que contienen N |
| DE102008017853A1 (de) | 2008-04-09 | 2009-10-15 | Merck Patent Gmbh | Thienopyrimidine |
| KR101147550B1 (ko) * | 2009-10-22 | 2012-05-17 | 한국과학기술연구원 | 단백질 키나아제 저해활성을 가지는 2,7-치환된 티에노［3,2-ｄ］피리미딘 화합물 |
| KR101094446B1 (ko) * | 2009-11-19 | 2011-12-15 | 한국과학기술연구원 | 단백질 키나아제 저해활성을 가지는 2,4,7-치환된 티에노［3,2-ｄ］피리미딘 화합물 |
| WO2012004900A1 (en) | 2010-07-09 | 2012-01-12 | Aska Pharmaceutical Co., Ltd. | Thienopyrimidine compounds |
| FR2988722B1 (fr) | 2012-04-03 | 2014-05-09 | Sanofi Sa | Nouveaux derives de thienopyrimidines, leurs procedes de preparation et leurs utilisations therapeutiques |
-
2012
- 2012-04-03 FR FR1253044A patent/FR2988722B1/fr active Active
-
2013
- 2013-02-04 UA UAA201411826A patent/UA112685C2/uk unknown
- 2013-04-02 SG SG11201406091RA patent/SG11201406091RA/en unknown
- 2013-04-02 CA CA2868685A patent/CA2868685C/en active Active
- 2013-04-02 EA EA201491820A patent/EA025558B1/ru not_active IP Right Cessation
- 2013-04-02 PL PL13716241.8T patent/PL2834248T3/pl unknown
- 2013-04-02 MA MA37384A patent/MA37384B1/fr unknown
- 2013-04-02 SI SI201330203A patent/SI2834248T1/sl unknown
- 2013-04-02 JP JP2015503860A patent/JP6096278B2/ja active Active
- 2013-04-02 PE PE2014001523A patent/PE20150289A1/es active IP Right Grant
- 2013-04-02 CN CN201710950612.0A patent/CN107652303B/zh active Active
- 2013-04-02 AU AU2013244992A patent/AU2013244992B2/en not_active Ceased
- 2013-04-02 RS RS20160436A patent/RS54850B1/sr unknown
- 2013-04-02 MY MYPI2014002724A patent/MY166151A/en unknown
- 2013-04-02 HR HRP20160649TT patent/HRP20160649T1/hr unknown
- 2013-04-02 EP EP13716241.8A patent/EP2834248B1/en active Active
- 2013-04-02 WO PCT/EP2013/056958 patent/WO2013150036A1/en not_active Ceased
- 2013-04-02 HU HUE13716241A patent/HUE027895T2/en unknown
- 2013-04-02 MX MX2014011921A patent/MX355104B/es active IP Right Grant
- 2013-04-02 CN CN201380029174.4A patent/CN104540834B/zh active Active
- 2013-04-02 PT PT137162418T patent/PT2834248E/pt unknown
- 2013-04-02 BR BR112014024489-8A patent/BR112014024489B1/pt not_active IP Right Cessation
- 2013-04-02 US US13/855,246 patent/US9115140B2/en active Active
- 2013-04-02 KR KR1020147030322A patent/KR102039764B1/ko active Active
- 2013-04-02 DK DK13716241.8T patent/DK2834248T3/en active
- 2013-04-02 ES ES13716241.8T patent/ES2577382T3/es active Active
- 2013-04-03 UY UY0001034725A patent/UY34725A/es not_active Application Discontinuation
- 2013-04-03 AR ARP130101067A patent/AR090572A1/es active IP Right Grant
- 2013-04-03 TW TW102112260A patent/TWI579288B/zh not_active IP Right Cessation
-
2014
- 2014-09-22 CR CR20140435A patent/CR20140435A/es unknown
- 2014-09-25 DO DO2014000216A patent/DOP2014000216A/es unknown
- 2014-09-26 ZA ZA2014/07021A patent/ZA201407021B/en unknown
- 2014-09-29 PH PH12014502180A patent/PH12014502180A1/en unknown
- 2014-09-30 TN TNP2014000415A patent/TN2014000415A1/fr unknown
- 2014-10-02 CL CL2014002661A patent/CL2014002661A1/es unknown
- 2014-10-02 IL IL234960A patent/IL234960A/en active IP Right Grant
- 2014-10-03 CO CO14219119A patent/CO7091179A2/es unknown
-
2015
- 2015-07-08 US US14/794,574 patent/US9744176B2/en active Active
-
2016
- 2016-06-15 CY CY20161100522T patent/CY1117843T1/el unknown
-
2017
- 2017-07-26 US US15/660,694 patent/US10220044B2/en active Active
-
2019
- 2019-01-10 US US16/245,131 patent/US10500212B2/en active Active
- 2019-10-30 US US16/668,555 patent/US10736904B2/en active Active
-
2020
- 2020-06-29 US US16/915,782 patent/US10980816B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR090572A1 (es) | Derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos | |
| AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR100438A1 (es) | Pirazolopiridinas y pirazolopirimidinas | |
| AR094299A1 (es) | Derivados de ftalazin-1(2h)-ona sustituidos | |
| AR092742A1 (es) | Piridinonas antifibroticas | |
| AR100886A1 (es) | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas | |
| AR106472A1 (es) | Inhibidores de acc y usos de los mismos | |
| AR100418A1 (es) | Compuestos y composiciones para inducir condrogénesis | |
| AR090005A1 (es) | Imidazo[1,2-a]pirimidinas y piridinas sustituidas | |
| AR104025A1 (es) | Carbamatos de piperazina como moduladores de magl y/o abhd6, procesos para su preparación y composiciones farmacéuticas | |
| AR087328A1 (es) | Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak | |
| AR092108A1 (es) | Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn | |
| AR096242A1 (es) | Inhibidores de acc y usos de los mismos | |
| AR089774A1 (es) | Derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR110405A1 (es) | Compuestos | |
| AR088423A1 (es) | Ligadores p1 ciclicos como inhibidores del factor xia | |
| AR095311A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
| AR098872A1 (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
| AR098337A1 (es) | Triazolopirazina | |
| AR105101A1 (es) | Derivados aminoácido, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| AR087841A1 (es) | Derivados de tetrahidrotriazolopirimidina | |
| AR086546A1 (es) | Derivados de 7h-purin-8(9h)-ona como inhibidores de jak | |
| AR096241A1 (es) | Inhibidores de acc y usos de los mismos | |
| AR099913A1 (es) | Derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR107042A1 (es) | Inhibidores de la tirosina quinasa de bruton y métodos de su uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |